AD/2724/2025 Acquisition of Eculizumab 300 mg Injection Solution in 30 ml IV Vials for ULSTMAD, EPE (A.U.E. 202502385_BCKMR)

This tender, referenced as AD/2724/2025, pertains to the acquisition of Eculizumab, specifically in the dosage of 300 mg per 30 ml vial for intravenous administration. The procurement is intended for ULSTMAD, EPE, which is a public healthcare entity. Eculizumab is a monoclonal antibody used in the treatment of various serious conditions, including atypical hemolytic uremic syndrome and generalized myasthenia gravis. The tender outlines the need for a reliable supply of this medication to ensure continuity of care for patients requiring this treatment. Interested suppliers are expected to comply with specific quality standards and regulatory requirements relevant to pharmaceutical products. The location of the procurement is within the jurisdiction of ULSTMAD, EPE, and suppliers must be capable of delivering the product in a timely manner. The tender emphasizes the importance of adherence to delivery schedules and the provision of necessary documentation to facilitate the procurement process. This acquisition is crucial for maintaining the health services provided by ULSTMAD, EPE, and ensuring that patients have access to essential medications.

This is a supplies contract in the health and medical services, transport and logistics and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 154,088.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.